Explore

Trendline Trendline
Minaris Achieves 100% Success in Manufacturing Chimeric Therapeutics' CAR-T Program for GI Cancer

Minaris Achieves 100% Success in Manufacturing Chimeric Therapeutics' CAR-T Program for GI Cancer

Minaris Achieves 100% Success in Manufacturing Chimeric Therapeutics' CAR-T Program for GI Cancer
Rapid Read Rapid Read
New Treatments for Pancreatic Cancer Offer Hope for Improved Survival Rates

New Treatments for Pancreatic Cancer Offer Hope for Improved Survival Rates

Experimental therapies for pancreatic cancer are generating optimism among researchers and patients. Revolution Medicines has developed a pill, daraxonrasib, that inhibits a protein driving tumor growth, showing promising results in a Phase 3 clinical trial. Patients treated with the drug had a median survival of 13.2 months compared to 6.7 months for those on chemotherapy. The FDA has fast-tracked the drug for approval, potentially making it available this year. Additionally, an mRNA vaccine developed by BioNTech and Genentech is showing promise in early trials, training the immune system to fight cancer cells post-surgery. These developments are seen as a significant advancement in treating one of the deadliest cancers.
Rapid Read Rapid Read
Nature Conference Highlights Pediatric Cancer Innovation and Global Care Disparities

Nature Conference Highlights Pediatric Cancer Innovation and Global Care Disparities

The Nature Conference on pediatric cancer care is set to convene experts, researchers, clinicians, policymakers, and patient advocates to tackle pressing challenges and opportunities in childhood cancer care. The event will focus on cutting-edge research in precision oncology, advances in molecular diagnostics, and the translation of novel therapies into clinical practice. A significant emphasis will be placed on addressing disparities in access to cancer care across different regions and populations, particularly between high- and low-resource settings. The conference aims to explore strategies for implementing sustainable, evidence-based interventions, strengthening health systems, and improving survival outcomes for children worldwide. By integrating scientific innovation with policy and advocacy, the event seeks to foster collaborative solutions that ensure equitable, high-quality care for all children with cancer.
Rapid Read Rapid Read
Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026

Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026

Rznomics, a clinical-stage biopharmaceutical company, has presented interim clinical data for its investigational anticancer therapy, RZ-001, at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, California. The study focuses on patients with hepatocellular carcinoma (HCC) who are refractory to or ineligible for transarterial chemoembolization (TACE) and have not received prior systemic therapy. The data revealed that the combination of RZ-001 with atezolizumab and bevacizumab achieved an objective response rate (ORR) of 38.5% (confirmed) and 46.2% (unconfirmed) based on RECIST v1.1 criteria. Under mRECIST criteria, the ORR was 61.5%, with a complete response rate of 23%. Importantly, no Grade 3 or higher adverse events were attributed to RZ-001, indicating a favorable safety profile.
Trendline Trendline
Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026

Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026

Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026
Rapid Read Rapid Read
Akamis Bio Reports Promising Results from Phase 1b Study of NG-350A in Rectal Cancer

Akamis Bio Reports Promising Results from Phase 1b Study of NG-350A in Rectal Cancer

Akamis Bio has announced encouraging preliminary results from its Phase 1b FORTRESS study of NG-350A, an oncolytic immunotherapy, in combination with chemoradiotherapy (CRT) for treating mismatch repair-proficient locally advanced rectal cancer (LARC). The study showed a composite response rate of 50% among the first 10 patients, with no serious adverse events related to NG-350A. This response rate is significantly higher than the expected 25% for CRT alone. The study aims to improve treatment outcomes for LARC patients, potentially offering a non-operative approach and organ preservation.
Trendline Trendline
Minaris Achieves 100% Success in Manufacturing for Chimeric Therapeutics' CAR-T Program

Minaris Achieves 100% Success in Manufacturing for Chimeric Therapeutics' CAR-T Program

Minaris Achieves 100% Success in Manufacturing for Chimeric Therapeutics' CAR-T Program
Rapid Read Rapid Read
Dana-Farber's CAR T-Cell Therapy Shows Promise in Early Myeloma

Dana-Farber's CAR T-Cell Therapy Shows Promise in Early Myeloma

Dana-Farber Cancer Institute has reported promising results from its phase 2 CAR-PRISM clinical trial, which tested CAR T-cell therapy in patients with high-risk smoldering multiple myeloma. The trial demonstrated durable remissions and deep eradication of malignant cells, with all treated patients achieving minimal residual disease negativity within two months post-infusion. The therapy, targeting B-cell maturation antigen, was administered before conventional chemotherapy, leveraging patients' intact immune systems for enhanced efficacy.
Trendline Trendline
Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value
Rapid Read Rapid Read
Dana-Farber's CAR T-Cell Therapy Shows Promise in Smoldering Multiple Myeloma

Dana-Farber's CAR T-Cell Therapy Shows Promise in Smoldering Multiple Myeloma

Dana-Farber Cancer Institute has reported promising results from its phase 2 CAR-PRISM clinical trial, which tested CAR T-cell therapy in patients with high-risk smoldering multiple myeloma (SMM). The trial, presented at the AACR Annual Meeting, demonstrated durable remissions and deep eradication of malignant cells. The therapy, ciltacabtagene autoleucel (cilta-cel), targets B-cell maturation antigen (BCMA) and was administered to patients before conventional chemotherapy. Over a median follow-up of 15.3 months, all patients achieved minimal residual disease negativity, with no disease relapse or mortality observed. The trial's success suggests that early intervention with CAR T-cell therapy could redefine treatment strategies for SMM.
Rapid Read Rapid Read
CAR-PRISM Phase 2 Trial Explores Ciltacabtagene Autoleucel for High-Risk Smoldering Multiple Myeloma

CAR-PRISM Phase 2 Trial Explores Ciltacabtagene Autoleucel for High-Risk Smoldering Multiple Myeloma

The CAR-PRISM phase 2 trial is investigating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel) in patients with high-risk smoldering multiple myeloma (HR-SMM). This single-center study involves a safety run-in phase followed by dose expansion, focusing on patients with specific high-risk features. The trial aims to assess the safety profile of cilta-cel, particularly in terms of dose-limiting toxicities and neurological adverse events. The study includes rigorous patient selection criteria to ensure safety and efficacy, with participants required to meet specific health and risk factor thresholds.
Rapid Read Rapid Read
Parker Institute Showcases Advances in Cancer Immunotherapy at AACR 2026

Parker Institute Showcases Advances in Cancer Immunotherapy at AACR 2026

The Parker Institute for Cancer Immunotherapy (PICI) is presenting significant research at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The event, running from April 17-22, features nearly 100 contributions from PICI leaders, investigators, and collaborators. These presentations highlight the institute's extensive work in cancer immunotherapy, including the largest plasma proteomics study for checkpoint inhibitor therapy and new methylation-based tools for monitoring tumor dynamics. Kristen Dahlgren, PICI's Chief of External Affairs, is co-chairing the meeting's program committee and leading sessions on improving trial efficiency and research impact. Antoni Ribas, Director of the PICI Center at UCLA, will receive the 2026 AACR-Margaret Foti Award for his leadership and achievements in cancer research.